Stuart Therapeutics announces first patient visit in ST-100 trial for dry eye
Stuart Therapeutics has announced the first patient first visit for its phase 3 clinical trial of ST-100 ophthalmic solution for patients with dry eye disease.
According to a company press release, ST-100 (vezocolmitide) is the first drug candidate based on PolyCol, the company’s synthesized polypeptide technology that mimics amino acid sequences found in collagen.
“We believe that vezocolmitide has the potential to solve the major unmet need for a fast and effective topical therapeutic that treats a broad range of dry eye disease patients,” Eric Schlumpf, Stuart’s president and CEO, said in the release.
The multicenter, randomized, double-masked, placebo-controlled study will assess the safety and efficacy of a single dose of ST-100 vs. placebo in 320 participants, the release stated.
“Since the completion of our phase 2 trial with ST-100, we have significantly expanded our portfolio, based on new research results on our mechanism of action, and its applicability to a number of important indications in ophthalmology,” Schlumpf said in the release. “In particular, our findings, coupled with the endpoint outcomes in our phase 2 trial, suggest the potential for a fast-acting, highly differentiated treatment for dry eye that can offer improved tear production, symptom relief, reduction in ocular surface damage and improvement in visual acuity.”